Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Immunodeficiency Virus-Type 1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT05222945
What this trial is testing

Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide

Who this might be right for
HIV-1-infection
ANRS, Emerging Infectious Diseases 34
Early research (Phase 1)Looking for participantsNCT07392372
What this trial is testing

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

Who this might be right for
HIV -1 Infection
BioNTech SE 67
Early research (Phase 1)Study completedNCT00001037
What this trial is testing

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 22
Not applicableStudy completedNCT00000900
What this trial is testing

The Effects of Illnesses on HIV Levels in the Body

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 26
Early research (Phase 1)Study completedNCT00001644
What this trial is testing

Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

Who this might be right for
HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID) 42
Early research (Phase 1)Study completedNCT00098163
What this trial is testing

Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 60
Post-approval studies (Phase 4)Ended earlyNCT01245101
What this trial is testing

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

Who this might be right for
HIV
University of Miami 15
Early research (Phase 1)Study completedNCT00097838
What this trial is testing

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

Who this might be right for
HIV Infections
AlphaVax, Inc. 96
Early research (Phase 1)Study completedNCT03393468
What this trial is testing

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 16
Large-scale testing (Phase 3)WithdrawnNCT01605084
What this trial is testing

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Who this might be right for
HIV
Bristol-Myers Squibb
Testing effectiveness (Phase 2)UnknownNCT00007449
What this trial is testing

Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors

Who this might be right for
HIV Infections
Dupont Applied Biosciences 30
Early research (Phase 1)Study completedNCT02599896
What this trial is testing

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

Who this might be right for
Prevention of HIV InfectionHIV AntibodiesMonoclonal Antibody, Human+1 more
National Institute of Allergy and Infectious Diseases (NIAID) 49
Post-approval studies (Phase 4)Study completedNCT02775929
What this trial is testing

Partners Demonstration Project of PrEP and ART

Who this might be right for
HIV Infection
University of Washington 1,013
Not applicableStudy completedNCT00002405
What this trial is testing

Amprenavir in HIV-Infected Patients

Who this might be right for
HIV Infections
Glaxo Wellcome
Early research (Phase 1)Study completedNCT00002261
What this trial is testing

A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

Who this might be right for
HIV Infections
Bristol-Myers Squibb
Large-scale testing (Phase 3)Study completedNCT04034862
What this trial is testing

Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs

Who this might be right for
HIV Infections
University of Liege 36
Large-scale testing (Phase 3)Looking for participantsNCT07708727
What this trial is testing

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

Who this might be right for
HIV-1-infection
Gilead Sciences 700
Post-approval studies (Phase 4)UnknownNCT00247494
What this trial is testing

Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients

Who this might be right for
HIV InfectionAtherosclerosis
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 90
Not applicableStudy completedNCT00007488
What this trial is testing

HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 164
Testing effectiveness (Phase 2)Study completedNCT00000825
What this trial is testing

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 72
Next Page